Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Wednesday 26 August →